A Study to Evaluate Biomarkers to Predict Efficacy of Abatacept in Rheumatoid Arthritis
Status:
Enrolling by invitation
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate if baseline levels of T cell associated
biomarkers predict efficacy of abatacept during 24 weeks of treatment in patients with
moderate to severe active Rheumatoid Arthritis (RA) who have had an inadequate response to
conventional disease modifying anti-rheumatic drugs (cDMARDs)